Allogenic stem cell transplantation (HCT) is a potentially curative treatment for patients with
various hematologic malignancies. Following HCT it is common practice to assess …

Background The importance of chimerism status in the very early period after hematopoietic
stem cell transplantation is unclear. We determined PBMC and T-cell donor chimerism 50 …

The utility of routine chimerism analysis as a prognostic indicator of subsequent outcomes
after allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning …

Incomplete donor chimerism (DC) after hematopoietic stem cell transplantation (HSCT) is
associated with reduced overall and disease-free survival and decreasing DC can precede …

Chimerism analysis after allogeneic hematopoietic stem cell transplantation serves to
confirm engraftment, indicate relapse of hematologic malignancy, and attribute graft failure …

Hematopoietic cell transplantation (HCT) has become a well-established treatment option
for a variety of malignant and nonmalignant diseases. Molecular analysis of chimerism is …

Allogeneic stem cell transplantation (allo-SCT) is the treatment of choice for many patients
with hematological malignancies, as well as some non-malignant hematological disorders …

Donor hematopoiesis or donor chimerism in the host following allogeneic bone marrow
transplantation (BMT) has appeared crucial to the engraftment process. However, as …

Approaches to the measurement of lymphohematopoietic chimerism have evolved from
laboratory research to important clinical tools. However, there has been no logical …

Increasing mixed chimerism (reemerging recipient cells) after allogeneic hematopoietic cell
transplant (allo-HCT) can indicate relapse, the leading factor determining mortality in blood …